Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The United States Patent and Trademark Office (USPTO) has granted a notice of allowance (NOA) to Epitomics for its Method for Identifying Differentially Expressed Proteins.
Subscribe to our email newsletter
The NOA will allow the California- based biotech company to identify differentially expressed proteins in cell samples.
The method, which uses libraries of antibodies, has a wide range of applications in the research and drug discovery markets, particularly in the field of cancer.
Epitomics CEO Guo-Liang Yu said that the USPTO’s approval will help them build a world class intellectual property estate around their proprietary rabbit monoclonal technology.
"We look forward to continued success in the development of our technology and patents, and ultimately to providing the best antibodies and solutions to researchers and clinicians," Yu said.